Edgewise Therapeutics said it will sell sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion, including $1.55 billion in cash upfront and as much as $1.1 billion in regulatory and commercial milestones.
The deal shifts Edgewise into a cardiovascular-focused company. After closing, its pipeline will center on EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003 for an undisclosed target.
The company said the upfront cash, together with its existing balance sheet, is expected to fully fund EDG-7500 development through potential approval. Edgewise also said it remains on track to report 12-week data from the CIRRUS-HCM Part D study of EDG-7500 in the second quarter of 2026, with a phase 3 start targeted for the fourth quarter of 2026.
For EDG-15400, Edgewise said it still plans to begin a phase 2 trial in HFpEF.
On the asset being sold, sevasemten is in late-stage testing in Becker and Duchenne muscular dystrophy. The Becker pivotal Grand Canyon cohort is fully enrolled with 175 participants and is powered at greater than 98% to show a statistically significant difference versus placebo. Top-line data are expected in the fourth quarter of 2026.
Edgewise said sevasemten has shown more than three years of sustained disease stabilization in clinical studies, with participants in the MESA open-label extension maintaining stable NSAA scores. The company also said the drug has had no discontinuations or dose reductions due to adverse events.
The transaction was unanimously approved by both boards and is expected to close in the third quarter of 2026. As a result of these announcements, the company's shares have moved 13.19% on the market, and are now trading at a price of $38.665. If you want to know more, read the company's complete 8-K report here.
